Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xenobella
- Development stage
- Phase 3
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Xenobella is an ophthalmic solution developed by Chong Kun Dang Pharmaceutical, primarily indicated for the treatment of dry eye syndrome and related corneal/conjunctival epithelial disorders, such as Sjögren's syndrome, Stevens-Johnson syndrome, and conditions arising from surgery, medication, trauma, or contact lens wear. Its active ingredient, sodium hyaluronate, is a biopolymer known for its viscoelastic properties and high water-retention capacity. When applied as eye drops, Xenobella lubricates the ocular surface, stabilizes the tear film, and protects corneal epithelial cells from dehydration. It also aids in repairing damaged cells and reducing inflammation, partly by inactivating the CD44 adhesion molecule. The clinical trial for Xenobella (CKD-350) specifically investigates a hypotonic 0.3% sodium hyaluronate formulation.
- Brand names
- Xenobella
Beyond the preview
Go deeper on Xenobella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xenobella.